Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Neuropsychopharmacol. 2012 Sep;15(8):1167-72. doi: 10.1017/S1461145711001945. Epub 2012 Jan 16.

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.

Author information

1
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. johan.lundberg@ki.se

Abstract

The aim of the present clinical positron emission tomography study was to examine if the 5-HTT is a common target, both for tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Serotonin transporter (5-HTT) occupancy was estimated during treatment with TCA, SSRI and mirtazapine in 20 patients in remission from depression. The patients were recruited from out-patient units and deemed as responders to antidepressive treatment. The radioligand [¹¹C]MADAM was used to determine the 5-HTT binding potential. The mean 5-HTT occupancy was 67% (range 28-86%). There was no significant difference in 5-HTT occupancy between TCA (n=5) and SSRI (n=14). 5-HTT affinity correlated with the recommended clinical dose. Mirtazapine did not occupy the serotonin transporter. The results support that TCAs and SSRIs have a shared mechanism of action by inhibition of 5-HTT.

PMID:
22243688
PMCID:
PMC3409583
DOI:
10.1017/S1461145711001945
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cambridge University Press Icon for PubMed Central
    Loading ...
    Support Center